GoodRx Director Scott Wagner Resigns from Board, Effective Jan 10

TL;DR

**GoodRx director Scott Wagner resigned, effective Jan 10.**

AI Summary

GoodRx Holdings, Inc. announced on January 16, 2024, that Scott Wagner resigned from its Board of Directors, effective January 10, 2024. This departure means the board loses a director with experience, which could impact strategic oversight. Investors should note this change as board composition can influence company direction and governance.

Why It Matters

The departure of a director can signal shifts in board dynamics or strategic direction, potentially affecting investor confidence and future company performance.

Risk Assessment

Risk Level: low — The departure of one director is a routine governance event and does not inherently pose a significant risk to the company's operations or financial health.

Analyst Insight

Investors should monitor future 8-K filings for announcements of new board appointments to assess the qualifications and experience of any replacements, which could influence future strategic decisions.

Key Players & Entities

• GoodRx Holdings, Inc. (company) — the registrant
• Scott Wagner (person) — departing director
• January 16, 2024 (date) — date of earliest event reported
• January 10, 2024 (date) — effective date of resignation

Forward-Looking Statements

• GoodRx will likely seek a replacement director to maintain board diversity and expertise. (GoodRx Holdings, Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.0001 — hich registered Class A Common Stock, $0.0001 par value per share GDRX The Nasdaq Sto

Filing Documents

• gdrx-20240116.htm (8-K) — 25KB
• 0001809519-24-000011.txt ( ) — 150KB
• gdrx-20240116.xsd (EX-101.SCH) — 2KB
• gdrx-20240116_lab.xml (EX-101.LAB) — 24KB
• gdrx-20240116_pre.xml (EX-101.PRE) — 12KB
• gdrx-20240116_htm.xml (XML) — 3KB

From the Filing

gdrx-20240116 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________ FORM 8-K ________________________________________ CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 16, 2024 ________________________________________ GoodRx Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) ________________________________________ Delaware 001-39549 47-5104396 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 2701 Olympic Boulevard Santa Monica, California 90404 (Address of Principal Executive Offices) (Zip Code) Registrant's Telephone Number, Including Area Code: ( 855 ) 268-2822 Not applicable (Former Name or Former Address, if Changed Since Last Report) ________________________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Class A Common Stock, $0.0001 par value per share GDRX The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 16, 2024, GoodRx Holdings, Inc. (the "Company") determined that the role currently held by Raj Beri, the Company's Chief Operating Officer (principal operating officer), will be eliminated and the Company's Board of Directors removed Mr. Beri as Chief Operating Officer, effective as of February 15, 2024 (the "Effective Date"). Mr. Beri is expected to remain Chief Operating Officer of the Company through the Effective Date to assist with the transition of his duties, and thereafter separate from the Company. Mr. Beri's separation constitutes a termination of employment by the Company and/or its subsidiaries without cause under the terms of each of Mr. Beri's (i) offer letter with GoodRx, Inc. (an indirect wholly owned subsidiary of the Company), dated May 6, 2022 (previously filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on May 9, 2022), and (ii) letter agreement with GoodRx, Inc., dated May 30, 2023 (previously filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on June 2, 2023). Effective as of the Effective Date, Mr. Beri's responsibilities will be assumed by other executives within the Company who will report directly to Scott Wagner, the Company's Interim Chief Executive Officer (principal executive officer), and Mr. Wagner, age 53, will be designated as the principal operating officer of the Company. Biographical and other information regarding Mr. Wagner, including his business experience and arrangements with the Company, may be found in the " Executive Officers" and "Transactions Related to Directors, Equity Holders and Executive Officers" sections of the Company's most recent Definitive Proxy Statement on Schedule 14A, filed with the SEC on May 1, 2023 , which information is incorporated herein by reference. The Company expects to enter into a Separation Agreement with Mr. Beri, the material terms of which will be disclosed in a subsequent Current Report on Form 8-K. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GOODRX HOLDINGS, INC. Date: January 17, 2024 By: /s/ Karsten Voermann Name: Karsten Voermann Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR